Platinum-resistant Ovarian Cancer Active Not Recruiting Phase 1 Trials for Mirvetuximab (DB16235)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

DBCOND0068919 (Platinum-resistant Ovarian Cancer)Active Not Recruiting1 IdentifierTitlePurposeDrugs
NCT03552471Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerTreatment